Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology ; volume:15 ; number:1 ; day:15 ; month:6 ; year:2024 ; pages:1-15 ; date:12.2024
Nature Communications ; 15, Heft 1 (15.6.2024), 1-15, 12.2024

Creator: Mastenbroek, Sophie E.
Vogel, Jacob W.
Collij, Lyduine E.
Serrano, Geidy E.
Tremblay, Cécilia
Young, Alexandra L.
Arce, Richard A.
Shill, Holly A.
Driver-Dunckley, Erika D.
Mehta, Shyamal H.
Belden, Christine M.
Atri, Alireza
Choudhury, Parichita
Barkhof, Frederik
Adler, Charles H.
Ossenkoppele, Rik
Beach, Thomas G.
Hansson, Oskar

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-024-49402-x

URN: urn:nbn:de:101:1-2408220850479.917179945191

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Mastenbroek, Sophie E.
Vogel, Jacob W.
Collij, Lyduine E.
Serrano, Geidy E.
Tremblay, Cécilia
Young, Alexandra L.
Arce, Richard A.
Shill, Holly A.
Driver-Dunckley, Erika D.
Mehta, Shyamal H.
Belden, Christine M.
Atri, Alireza
Choudhury, Parichita
Barkhof, Frederik
Adler, Charles H.
Ossenkoppele, Rik
Beach, Thomas G.
Hansson, Oskar
SpringerLink (Online service)

Other Objects (12)

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

LRP10 and α-synuclein transmission in Lewy body diseases

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Towards a unified protocol for handling of CSF before β-amyloid measurements

Fluid biomarkers in Alzheimer’s disease – current concepts

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

LRP10 and α-synuclein transmission in Lewy body diseases

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Towards a unified protocol for handling of CSF before β-amyloid measurements

Fluid biomarkers in Alzheimer’s disease – current concepts

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

LRP10 and α-synuclein transmission in Lewy body diseases

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Towards a unified protocol for handling of CSF before β-amyloid measurements

Fluid biomarkers in Alzheimer’s disease – current concepts

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

LRP10 and α-synuclein transmission in Lewy body diseases

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Towards a unified protocol for handling of CSF before β-amyloid measurements

Fluid biomarkers in Alzheimer’s disease – current concepts

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

LRP10 and α-synuclein transmission in Lewy body diseases

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Towards a unified protocol for handling of CSF before β-amyloid measurements

Fluid biomarkers in Alzheimer’s disease – current concepts

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

LRP10 and α-synuclein transmission in Lewy body diseases

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

External validation of a 3-step falls prediction model in mild Parkinson’s disease

Towards a unified protocol for handling of CSF before β-amyloid measurements

Fluid biomarkers in Alzheimer’s disease – current concepts

Related objects

Reset password